BioAge Labs, Inc.

BIOA

Held by 1 specialist biotech fund

Share on X

Fund Holdings

OrbiMed Advisors

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management3.7%Feb 14, 2025

SC 13GRA Capital Management6.2%Oct 7, 2024

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 790,901Value: $10.5M

# Signal Note: OrbiMed Initiates $10.5M Position in BioAge Labs **Why it matters:** OrbiMed's entry signals confidence in BioAge's longevity platform, which targets aging-related diseases through epigenetic biomarkers and cellular reprogramming—a space showing clinical momentum following recent partial reprogramming data in human studies. The $10.5M stake (790,901 shares) from one of healthcare's most selective allocators suggests institutional validation ahead of near-term clinical readouts, likely catalysts including IND-enabling studies or aging biomarker partnerships with pharma.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

APLS1 fund RNA1 fund IRON1 fund ANRO1 fund FOLD1 fund BCAX1 fund ARGX1 fund PRAX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: